Serum percent-free PSA does not predict extraprostatic spread of prostate cancer

American Journal of Clinical Pathology

Volumn 109, Issue 5, 1998, Pages 533-539

  Henricks, Walter H ^a,b   England, Barry G ^a   Giacherio, Donald A ^a   Oesterling, Joseph E ^a   Wojno, Kirk J ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Analyte stability; Free PSA; Free to total PSA ratio; Percent free PSA; Prostate cancer staging; Prostate specific antigen

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER STAGING; FREEZING; HUMAN; IMMUNOASSAY; MAJOR CLINICAL STUDY; MALE; MALE GENITAL TRACT CANCER; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; THAWING;

EID: 0031943262     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajcp/109.5.533     Document Type: Article

References (31)

1. Sinha AA, Wilson MJ, Gleason DF. Immunoelectron microscopic localization of prostatic specific antigen in human prostate by the protein A-gold complex. Cancer. 1987;60:1288-1293.
2. Catalona WJ, Smith DS, Ratliff TL, et al. Measurement of prostate specific antigen in serum as a screening test for prostate cancer. N Engl J Med. 1991;324:1156-1161.
3. Catalona WJ, Smith DS, Ratliff TL, et al. Detection of organ-confined prostate cancer is increased through prostate specific antigen-based screening. JAMA. 1993;270:948-954.
4. Catalona WJ, Richie JP, Ahmann FR, et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6630 men. J Urol. 1994;151:1283-1290.
5. Gann PH, Hennekens CH, Stampfer MJ. A prospective evaluation of plasma prostate specific antigen for detection of prostatic cancer. JAMA. 1995;273:289-294.
6. Lange PH, Ercole CH, Lightner DJ, et al. The value of serum prostate specific antigen determinations before and after radical prostatectomy. J Urol. 1989;141:873-879.
7. Hudson MA, Bahnson RR, Catalona WJ. Clinical use of prostate specific antigen in patients with prostate cancer. J Urol. 1989;142:1011-1017.
8. Partin AW, Oesterling JE. The clinical usefulness of prostate specific antigen: update 1994. J Urol. 1994;152:1358-1368.
9. Partin AW, Yoo J, Carter HB, et al. The use of prostate specific antigen, clinical stage, and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol. 1993;150:110-114.
10. Lange PH, Ercole CH, Lightner DJ, et al. The value of serum prostate specific antigen determinations before and after radical prostatectomy. J Urol. 1989;141:873-879.
11. Kleer E, Larson-Keller JJ, Zincke H, et al. Ability of preoperative serum prostate specific antigen value to predict pathologic stage and DNA ploidy. Urology. 1993;41:207-216.
12. Kleer E, Oesterling JE. PSA and staging of localized prostate cancer. Urol Clin North Am. 1993;20:695-704.
13. Middleton RG, Thompson IM, Austenfeld MS, et al. Prostate Cancer Clinical Guidelines Panel summary report on the management of clinically localized prostate cancer. J Urol. 1995;154:2144-2148.
14. Christensson A, Laurell CB, Lilja H. Enzymatic activity of prostate specific antigen and its reaction with extracellular serine proteinase inhibitors. Eur J Biochem. 1990;194:755-763.
15. 1-antichymotrypsin is the major form of prostate specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Res. 1991;51:222-226.
16. 1-antichymotrypsin. Clin Chem. 1991;37:1618-1625.
17. McCormack RT, Rittenhouse HG, Finlay JA, et al. Molecular forms of prostate specific antigen and the human kallikrein gene family: a new era. Urology. 1995;45:729-744.
18. 1-antichymotrypsin as an indicator of prostate cancer. J Urol. 1993;150:100-105.
19. Catalona WJ, Smith DS, Wolfert RL, et al. Evaluation of percentage of free serum prostate specific antigen to improve specificity of prostate cancer screening. JAMA. 1995;274: 1214-1220.
20. Luderer AA, Chen YT, Soriano, TF, et al. Measurement of the proportion of free to total prostate specific antigen improves the diagnostic performance of prostate specific antigen in the diagnostic gray zone of total prostate specific antigen. Urology. 1995;46:187-194.
21. Vashi AR, Wojno KJ, Henricks WH, et al. Determination of the 'reflex range' and appropriate cutpoints for percent-free prostate-specific antigen in 413 men referred for prostatic evaluation using the AxSM system. Urology. 1997;49:19-27.
22. Henricks WH, England BG, Giacherio DA, et al. A comparison of serum levels of total prostate-specific antigen (PSA) and the free to total PSA ratio in detecting prostatic adenocarcinoma. Clin Chem. 1996;42:S263. Abstract.
23. Sakr WA, Wheeler TM, Blute M, et al. International consultation on prostatic intraepithelial neoplasia and pathological staging of prostatic carcinoma, Rochester, Minnesota, November 3-4, 1995. Cancer. 1996;78:320-381.
24. Cuny C, Pham L, Kramp W, et al. Evaluation of a two-site immunoradiometric assay for measurement of noncomplexed (free) PSA. Clin Chem. 1996;42:1243-1249.
25. Jacobsen SJ, Klee GG, Lilja H, et al. Stability of serum prostate-specific antigen determination across laboratory, assay, and storage time. Urology. 1995;45:447-453.
26. Woodrum D, French C, Shamel LB. Stability of free prostate-specific antigen in serum samples under a variety of sample collection and sample storage conditions. Urology. 1996;48(6A):33-39.
27. Zietman AL, Shipley WU, Willett CG. Residual disease after radical surgery or radiation therapy for prostate cancer: clinical significance and therapeutic implications. Cancer. 1993;71(suppl 3):959-969.
28. 1-antichymotrypsin production in PSA-producing cells is common in prostate cancer but rare in benign prostatic hyperplasia. Urology. 1994;43:427-434.
29. Arcangeli CG, Shepherd DL, Smith DS, et al. Correlation of percent free PSA with pathologic features of prostatic carcinomas. J Urol. 1996:155:415. Abstract.
30. Pannek J, Subong EN, Jones KA, et al. The role of free/total prostate-specific antigen ratio in the prediction of final pathologic stage for men with clinically localized prostate cancer. Urology. 1996;48(6A):51-54.
31. Bangma CH, Kranse R, Blijenberg BG, et al. The free-to-total prostate specific antigen ratio for staging prostate carcinoma. J Urol. 1997:157:544-547.